FY2026 EPS Estimates for Indivior Boosted by Northland Capmk

Indivior PLC (NASDAQ:INDV) – Northland Capmk boosted their FY2026 earnings estimates for shares of Indivior in a report issued on Thursday, October 30th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of $2.25 for the year, up from their previous estimate of $2.00. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million during the quarter, compared to analyst estimates of $257.66 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. Indivior has set its FY 2025 guidance at EPS.

Several other analysts have also weighed in on the company. Piper Sandler restated an “overweight” rating and issued a $41.00 price objective (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. HC Wainwright lifted their price objective on shares of Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Craig Hallum reissued a “buy” rating and set a $41.00 target price on shares of Indivior in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.17.

Indivior Stock Performance

Shares of NASDAQ INDV opened at $32.00 on Monday. The stock has a fifty day moving average price of $24.53 and a two-hundred day moving average price of $18.58. The firm has a market cap of $4.41 billion, a P/E ratio of 51.61 and a beta of 0.70. Indivior has a 1 year low of $7.62 and a 1 year high of $32.14.

Hedge Funds Weigh In On Indivior

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Indivior by 16.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after purchasing an additional 666 shares during the period. CWM LLC acquired a new stake in shares of Indivior in the third quarter worth $25,000. Raymond James Financial Inc. acquired a new position in Indivior during the second quarter valued at $26,000. Campbell & CO Investment Adviser LLC lifted its stake in Indivior by 3.5% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 53,782 shares of the company’s stock worth $1,297,000 after acquiring an additional 1,834 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd boosted its position in Indivior by 17.4% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock worth $375,000 after acquiring an additional 3,769 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.